Crizotinib loaded polydopamine-polylactide-TPGS nanoparticles in chemotherapy for non-small cell lung cancer

Abstract Objective: To evaluate the effect of crizotinib loaded polydopamine-polylactide-TPGS nanoparticles (CZT/pD-PT NPs) on non-small cell lung cancer (NSCLC) and its safety.Methods: After the synthesis of CZT/pD-PT NPs, their characterization was evaluated and its effects on PC-9 cell viability and apoptosis were determined. In vivo experiment was further performed to evaluate the anti-NSCLC efficacy of CZT/pD-PT NPs. TUNEL assay and Western blot were respectively applied for the determination of cell apoptosis and apoptosis-related protein expression, while liver function-related index expression detection and liver histopathological detection were used to evaluate the hepatotoxicity of CZT/pD-PT NPs. Results: Compared with free CZT, CZT/pD-PT NPs had a slow-release effect and promoted the cellular uptake of CZT. In addition, CZT/pD-PT NPs significantly inhibited PC-9 cell viability and promoted cell apoptosis both in vitro and in vivo, showing superior cytotoxicity. At the same time, CZT/pD-PT NPs had no significant effect on liver tissue morphology liver and function-related indicators such as ALP, ALT, AST and DBIL.Conclusion: CZT/pD-PT NPs has excellent anti-NSCLC effect with low hepatotoxicity, which can be served as a novel drug delivery system to improve the efficacy of chemotherapy for NSCLC.